乐观
$150.52
情景价格
$266.900
-4.084 (-1.53%)收盘时
IQVIA Holdings Inc. is a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. Its segments include Commercial Solutions and Research & Development Solutions. Its commercial solutions provide mission critical information, advanced analytics, technology solutions, health care provider services (including contract sales), and patient engagement services to the Company’s life science clients. Its research & development solutions primarily serve biopharmaceutical customers, provide outsourced clinical research, clinical trial and real-world research related services. The Company offers clinical products, commercial products, compliance, safety, reg products, real world products, and others. Its clinical products include planning suite, grant plan, site suite, clinical trial payments, investigator site portal, one home for sites, patient engagement suite and others.
IQVIA Holdings Inc is a good buy right now due to its strong financial performance and positive market sentiment. The current price of $266.90 is below the average analyst price target of $305, suggesting a potential upside of approximately 14%. Additionally, the forward P/E ratio is 18.42, which is attractive compared to the current P/E of 32.18, indicating that the stock may be undervalued relative to its future earnings potential. However, the main risk is the insider selling, with executives reducing their holdings by 19%, which may signal caution regarding future performance.
BofA
$305
2026-10-09
BofA
2026-10-09
目标价
$305
Mizuho
$300
2026-10-07
Mizuho
2026-10-07
目标价
$300
Barclays
$300
2026-10-07
Barclays
2026-10-07
目标价
$300
UBS
$345
2026-09-30
UBS
2026-09-30
目标价
$345
RBC Capital
$319
2026-09-29
RBC Capital
2026-09-29
目标价
$319
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

IQVIA and Veeva Expand Partnership with New Standard Applications

IQVIA Launches Life Science Models to Predict Clinical Trial Outcomes

IQVIA Launches IQVIA Explorer™ to Enhance Commercial Decision-Making

IQVIA Prices $2 Billion Senior Notes Offering

IQVIA Launches AI-Powered Predictive Clinical Development Solution
IQVIA Holdings Inc. is a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. Its segments include Commercial Solutions and Research & Development Solutions. Its commercial solutions provide mission critical information, advanced analytics, technology solutions, health care provider services (including contract sales), and patient engagement services to the Company’s life science clients. Its research & development solutions primarily serve biopharmaceutical customers, provide outsourced clinical research, clinical trial and real-world research related services. The Company offers clinical products, commercial products, compliance, safety, reg products, real world products, and others. Its clinical products include planning suite, grant plan, site suite, clinical trial payments, investigator site portal, one home for sites, patient engagement suite and others. It operates in the Healthcare sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).
IQVIA Holdings Inc is a good buy right now due to its strong financial performance and positive market sentiment. The current price of $266.90 is below the average analyst price target of $305, suggesting a potential upside of approximately 14%. Additionally, the forward P/E ratio is 18.42, which is attractive compared to the current P/E of 32.18, indicating that the stock may be undervalued relative to its future earnings potential. However, the main risk is the insider selling, with executives reducing their holdings by 19%, which may signal caution regarding future performance.
17 analysts cover IQV: 9 rate it Buy, 8 Hold and 0 Sell. The average price target is 258.31.
暂无帖子
注册或登录后参与讨论本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。